Trial Profile
A Phase Ib, Multi-center Study of Ningetinib(CT053PTSA) in Combination With Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative Who Have Progressed After EGFR TKI Treatment
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 24 Jun 2022
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary) ; Ningetinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sunshine Lake Pharma
- 20 Jun 2022 Planned End Date changed from 17 Nov 2021 to 17 Jul 2023.
- 20 Jun 2022 Planned primary completion date changed from 17 Aug 2021 to 17 Jul 2023.
- 20 Jun 2022 Status changed from recruiting to active, no longer recruiting.